Livzon Pharmaceutical updates on A-share repurchase, H-share buyback yet to begin

Livzon Pharmaceutical Group Co., Ltd. announced the progress of its A-share repurchase program as of November 30, 2025. The company repurchased 16,193,259 A-shares through centralized bidding, representing 1.79% of its total share capital. The highest price paid was RMB 41.99 per share, and the lowest was RMB 33.21 per share. The total capital utilized for the A-share repurchase, excluding transaction fees, amounted to RMB 600,217,787.75. These repurchased A-shares are intended for cancellation to reduce registered capital, in line with previously approved repurchase plans.

The total issued share capital for A-shares remains at 604,293,313 shares, while the total issued share capital for H-shares is 299,807,117 shares as of November 30, 2025. The company clarified that its H-share repurchase, authorized by the board to be conducted on the Hong Kong Stock Exchange at a price not exceeding 5% of the average closing price of the preceding five trading days, has not yet commenced as of the reporting date.

The company's statutory/registered share capital for A-shares stands at RMB 604,293,313, and for H-shares at RMB 299,807,117, bringing the total statutory/registered share capital to RMB 904,100,430. Livzon Pharmaceutical Group pledges to comply with relevant regulations from the Shenzhen Stock Exchange and Hong Kong Stock Exchange regarding future disclosures on its repurchase activities.